Sage Therapeutics, Inc. (SAGE) Cut to “Hold” at BidaskClub
BidaskClub downgraded shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) from a buy rating to a hold rating in a report released on Wednesday morning.
Several other research firms also recently weighed in on SAGE. Leerink Swann reiterated an outperform rating and set a $97.00 target price (up from $90.00) on shares of Sage Therapeutics in a research report on Tuesday, June 20th. ValuEngine upgraded Sage Therapeutics from a sell rating to a hold rating in a research report on Friday, June 2nd. Stifel Nicolaus started coverage on Sage Therapeutics in a research report on Wednesday, August 9th. They set a buy rating and a $104.00 target price on the stock. Needham & Company LLC reiterated a buy rating and set a $82.00 target price on shares of Sage Therapeutics in a research report on Tuesday, June 13th. Finally, Canaccord Genuity set a $110.00 target price on Sage Therapeutics and gave the stock a buy rating in a research report on Saturday, August 5th. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Sage Therapeutics currently has a consensus rating of Buy and a consensus price target of $89.64.
Sage Therapeutics (NASDAQ:SAGE) opened at 78.63 on Wednesday. The company’s market cap is $2.94 billion. Sage Therapeutics has a 52-week low of $35.74 and a 52-week high of $90.43. The firm’s 50-day moving average is $82.24 and its 200-day moving average is $72.59.
Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by $0.25. During the same period in the previous year, the firm posted ($1.08) earnings per share. On average, equities research analysts anticipate that Sage Therapeutics will post ($7.38) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/26/sage-therapeutics-inc-sage-cut-to-hold-at-bidaskclub.html.
A number of large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 138 shares in the last quarter. Turner Investments LLC purchased a new stake in shares of Sage Therapeutics during the second quarter valued at approximately $159,000. Dubuque Bank & Trust Co. purchased a new stake in shares of Sage Therapeutics during the second quarter valued at approximately $167,000. Canada Pension Plan Investment Board purchased a new stake in shares of Sage Therapeutics during the second quarter valued at approximately $175,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in shares of Sage Therapeutics during the first quarter valued at approximately $180,000.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.